Acute Limb Ischemia

Gilliland, Charles A.; Shah, Jay; Martin, Jonathan G.; Miller, Michael J.

doi:10.1053/j.tvir.2017.10.008

Cited by 28 publications

(27 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The AGGF1, HIF-1α, and VEGF mRNA levels in the musculus gastrocnemius of the three dose groups were significantly higher than those of the model group (P<0.05). These findings reflect that AGGF1 eukaryotic expression vector can increase AGGF1, HIF-1α, and VEGF mRNA levels in the musculus gastrocnemius of mice with lower limb ischemia [7,8]. In this study, cells at the wound of mice with lower limb ischemia were in an oxygen-deficient environment, which might be one of the reasons for the upregulated HIF-1α expression.…”

Section: Preliminary Exploration On the Therapeutic Effect Of Aggf1 Imentioning

confidence: 76%

Preliminary exploration on the therapeutic effect of AGGF1 in mice with lower limb ischemia and corresponding molecular mechanism

Sun¹,

Li²,

Shao³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

Objective: This study aimed to observe the therapeutic effect of angiogenic factor with G-patch and FHA domain 1 (AGGF1) in mice with lower limb ischemia and determine the corresponding molecular mechanism. Methods: A total of 40 C57BL/6 male mice were selected. 32 mice were chosen to establish the lower limb ischemia model and divided into the low-dose, middle-dose, high-dose, and model groups. The remaining 8 mice comprised the sham-operation group and underwent separation of the left arteria femoralis and arteria iliaca externa (same with the model group). AGGF1 was injected once every day for 4 weeks. Tissue necrosis, dyskinesia scores, and recovery percentage of lower limb bloodstream at 1, 2, and 4 weeks after AGGF1 injection were compared. All mice were killed after 4 weeks of treatment. AGGF1, hypoxia-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF) mRNA and protein levels in the musculus gastrocnemius at the operation side were measured and compared. Results: Tissue necrosis and dyskinesia scores at 1, 2 and 4 weeks after AGGF1 injection and AGGF1, HIF-1α, and VEGF mRNA and protein levels in the musculus gastrocnemius of different groups were compared. The sham-operation group achieved the lowest values, followed by the middle-dose, highdose, low-dose, and model groups successively. Statistically significant differences between any two groups were found (P<0.05). Intra-group comparison revealed a slight change in the tissue necrosis score of the sham-operation group (P>0.05). The dyskinesia scores of the sham-operation group and the three dose groups sharply dropped as time passed (P<0.05), whereas those of the model group dramatically increased (P<0.05). Conclusions: AGGF1 (2 μg/mL) can improve tissue necrosis and dyskinesia and accelerate lower limb bloodstream recovery of mice with lower limb ischemia. The mechanism is speculated to be related to an upregulated expression of AGGF1, HIF-1α, and VEGF mRNA and proteins.

show abstract

Section: Preliminary Exploration On the Therapeutic Effect Of Aggf1 Imentioning

confidence: 76%

Preliminary exploration on the therapeutic effect of AGGF1 in mice with lower limb ischemia and corresponding molecular mechanism

Sun¹,

Li²,

Shao³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

show abstract

“…3 Thrombosis is most often due to prior bypass grafts or atherosclerotic disease in the region of occlusion which is associated with a history of diabetes, smoking, known peripheral arterial disease, myocardial infarction, or cerebrovascular accident. 1,2 Embolism, from a distant source, is most often due to atrial fibrillation, acute myocardial infarction, left ventricular dysfunction, and prosthetic cardiac valves. 1,6 Less common risk factors for acute limb ischemia include systemic thrombophilia, dissection, intimal hyperplasia, vasculitis, and aneurysm thrombosis.…”

Section: Risk Factorsmentioning

confidence: 99%

“…7 A focused physical examination includes evaluation of pulses (tactile and Doppler), sensation to light touch, and muscular strength. 2 Findings of acute limb ischemia include absent pulses, decreased strength, cool skin, and reduced sensation. 1…”

Section: Physical Examination Findingsmentioning

confidence: 99%

“…and contraindications to thrombolysis. 2 Patients with acute limb ischemia will present with new or worsening claudication or, more commonly, rest pain, numbness, weakness, and change in the color or temperature of the extremity. 1,2 Clinical symptoms may be recalled by employing the "6 Ps": pain, paresthesia, paralysis, pallor, poikilothermia (cool extremity), and pulselessness.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Acute Limb Ischemia Therapies: When and How to Treat Endovascularly

Hage

McDevitt

Vadlamudi

2018

Semin intervent Radiol

View full text Add to dashboard Cite

Acute limb ischemia is an emergent limb and life-threatening condition with high morbidity and mortality. An understanding of the presentation, clinical evaluation, and initial workup, including noninvasive imaging evaluation, is critical to determine an appropriate management strategy. Modern series have shown endovascular revascularization for acute limb ischemia to be safe and effective with success rates approaching surgical series and with similar, or even decreased, perioperative morbidity and mortality. A thorough understanding of endovascular techniques, associated pharmacology, and perioperative care is paramount to the endovascular management of patients presenting with acute limb ischemia. This article discusses the diagnosis and strategies for endovascular treatment of acute limb ischemia.

show abstract

“…13 Unfortunately, 50% of CLI patients do not present any symptoms 6 months prior to the onset of CLI, which makes it difficult to establish an effective preventive strategy.…”

Section: -12mentioning

confidence: 99%

Therapeutic Angiogenesis for Severely Ischemic Limbs — from Bench to Bedside in Acute Vascular Care

Benedek

Kovács

Benedek

2017

Journal of Cardiovascular Emergencies

View full text Add to dashboard Cite

Severe limb ischemia represents a critical condition, being associated with high morbidity and mortality rates. Patients with critical limb ischemia (CLI) require urgent initiation of interventional or surgical treatment, as restoration of the blood flow is the only way to ensure limb salvage in these critical cases. At the same time, in acute limb ischemia, a dramatic form of sudden arterial occlusion of the lower limbs, the integrity of the limb is also seriously threatened in the absence of urgent revascularization. From patients with CLI, 40% are "no option CLI", meaning patients in whom, due to anatomical considerations or to the severity of the lesions, there is no possibility to perform interventional or surgical treatment or they have failed. Therapeutic angiogenesis has been proposed to serve as an effective and promising alternative therapy for patients with severe limb ischemia who do not have any other option for revascularization. This review aims to present the current status in therapeutic angiogenesis and the role of different approaches (gene or cell therapy, intra-arterial vs. intramuscular injections, different sources of cells) in increasing the rates of limb salvage in patients with severe ischemia of the lower limbs.

show abstract

Acute Limb Ischemia

Cited by 28 publications

References 34 publications

Preliminary exploration on the therapeutic effect of AGGF1 in mice with lower limb ischemia and corresponding molecular mechanism

Preliminary exploration on the therapeutic effect of AGGF1 in mice with lower limb ischemia and corresponding molecular mechanism

Acute Limb Ischemia Therapies: When and How to Treat Endovascularly

Therapeutic Angiogenesis for Severely Ischemic Limbs — from Bench to Bedside in Acute Vascular Care

Contact Info

Product

Resources

About